BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. Some articles will have been accepted based in part or entirely on reviews undertaken for other BMJ Group journals. These will be reproduced where possible.
REVIEWER

Dimairo, Munyaradzi University of Sheffield, School of Health and Related Research REVIEW RETURNED
25-Oct-2013
GENERAL COMMENTS
Statistical analysis approach seems to be fine, however, authors should clarify what methods were used to calculate the 95% confidence intervals of adverse reations/events which are rare events (that is, they are always close to the boundary space of 0). So, asymptotic properties do not apply. Please see the attached file using the correct method. In addition, they need to state in full the Higgins and Thompson I^2 statistics and a reference would be great for the audience.
Careful examination of possible sources of heterogeneity is required.
For instance, what are the possible explanations why the Xu et al (2010) study is too extreme given that the treatment duration and follow up (~5 yrs) was much shorter compared to other studies? How did their classification of ADRs differ from other studies? More information is needed.
Authors should avoid the term conversional and state the online search engines used. It is not clear on whether they considered participants with at least one ADR event or including cumulative counting of repeated events. I suspect they considered the former. If so, then they need to be clear and highlight as a possible limitation that the number of repeated events were not considered which is important, especially for ADR. In theory, another option would be to model repeated ADR assuming individual data is available. However, I do not think it would add any value given that the events are very small.
One of the major weaknesses of this work is the unavailability of adverse events data considering that 141(~96%) of the studies were excluded due to incompleteness or nothing at all. This is worrying indeed. Did authors had a chance to find out the reasons behind this -is it because the adverse events were not collected at all in these individual studies or they did not report it or it's something else? In addition, of these excluded studies, was there any information on efficacy/effectiveness of Cfz?
On fig 1 -how many conference abstracts were manually reviewed?
General comment -In theory, we know that adverse events are rare events and it requires hundreds of thousands of patients to definitively understand the safety profile of a drug unless the drug is extremely dangerous.
Clarity and additional information is required, especially on some sections which are in the protocol but not even stated in the manuscript. For instance, on bias assessment.
They need to rerun the meta-analysis using confidence intervals calculated using the wilson score method.
I would advise the authors to recalculate the confidence interval using wilson score approach (see attached files) and repeat the fixed and random effect model for the meta analysis.
-I find it a bit confusing to link the protocol and the manuscript with relation to other objectives such as efficacy/effectiveness of Cfz. Was this a systematic review of systematic reviews because the protocol is silent on this? If so, is it possible to synthesise the effectiveness evidence across all these studies/systematic reviews through an updated meta analysis. Clarification is required?
I would suggest rephrasing the first paragraph on the discussion to include some words of caution on the findings due to limited data on ADRs similar to what has been done on the conclusion section of the abstract. As it stands, if I read it as a reader I might be tempted to over intepret the findings in support of Cfz safety.
The protocol talks about bias assessment using the Cochrane Collaboration's risk of bias framework and categorisation of studies as low, high or unclear which is great. However, there is nothing in the manuscript about this? In addition, the approach described fits well with systematic reviews of randomised controlled trials. I am therefore wondering how issues like randomisation, concealment and blinding say are applicable to this study given that you only considered observational studies? Could you please clarify this or there is something that I'm missing here?
We would like to thank the reviewer for the helpful comments. We agree with the comments provided and have made the suggested changes.
Comment 1: -"Page 0. In the cover page the names of the authors are not presented the same way as on the first page of the manuscript."
Authors' response: We have double-checked the affiliations of all of the named co-authors and will ensure that they are faithfully reproduced when entered into the online submission portal.
Comment 2: -Page 3, line 23, and page 4 lines 41-42. Adverse drug reaction (ADR) is never clearly defined. It is only referred to on page 4, lines 41-42 with references 20, 21. That is not sufficient. The authors should briefly but clearly indicate how they appreciated and reported the side-effects and the adverse drug reactions (if they are different) because it is a crucial part of their study. This comment is valid also for the title of Figure 2 for which the reviewer is wondering how can the readers understand the meaning of "…all reported adverse events associated with or ADRs (???) attributed to…)" For the readers (and the reviewer), the difference between adverse events and adverse drug reaction (ADR) should be clearly explained.
Authors' response: As suggested, we have substantially rewritten the paragraph (page 4, lines 27-38) to distinguish between ADRs and adverse events. An ADR was defined as an "appreciably harmful or unpleasant reaction caused by a drug that is serious enough to warrant the discontinuation or revision of treatment." In contrast, adverse events included all "undesirable reactions reported by patients or clinicians, including mild reactions that had no bearing on treatment."
Comment 3: -Page 4. Statistical analysis. The statistical approach is certainly of first class, but it is written in a highly specialized language far above the understanding of the usual reader. Either the meaning of the following sentences, words, acronyms and signs is given in plain English language, or even better the authors provide only the precise references of the statistical methods that were used and spare the suffering of the basic reader Authors' response: We appreciate the reviewer's suggestion and agree that the readability of the paper could be improved. We have included the relevant passages as part of the Supplemental Appendix that can be accessed by interested readers online. We have added references 23 and 24 in the main text (page 5, line 7) in lieu of the more extended description in the Appendix.
Comment 4: -The following sentence (lines 52-56) may be essential but has no meaning for the reviewer and certainly for the usual reader: "From this analysis, we determined that the DerSimonian and Laird random effects model was more appropriate for pooling estimates of adverse event frequencies (I2=98.7%; P<0.001),24 whereas the inverse-variance weighted fixed effects model was used for ADRs (I2=11.5%; P=0.34)".
Authors' response: As described in reply to comment #3, we have revised the relevant passages and referred the interested reader(s) to the Supplemental Appendix.
REVIEWER 2
We would like to thank the reviewer for careful consideration of the statistical analysis and helpful comments on our paper.
Comment 5: -Statistical analysis approach seems to be fine, however, authors should clarify what methods were used to calculate the 95% confidence intervals of adverse reations/events which are rare events (that is, they are always close to the boundary space of 0). So, asymptotic properties do not apply. Please see the attached file using the correct method. In addition, they need to state in full the Higgins and Thompson I^2 statistics and a reference would be great for the audience.
Authors' response: We appreciate the reviewer's suggestion ad agree that the Wilson score method for deriving confidence intervals is an appropriate choice when events are rare. We have added this in our Methods (page 5, lines 7-8). As the confidence intervals did not vary significantly from those previous stated and in light of another reviewer's comments, we have included the calculations as part of the web appendix. Specifically, we state: the "high level of adverse events could be attributed to the high frequency of reported skin discolouration (36 patients), a known reaction to Cfz treatment, but only two patients discontinued Cfz altogether."
Comment 7: -Authors should avoid the term conversional and state the online search engines used.
Authors' response: We did not find reference to this term in the text of the paper. We list the online search engines used in lines 9-10 of page 4.
Comment 8: -It is not clear on whether they considered participants with at least one ADR event or including cumulative counting of repeated events. I suspect they considered the former. If so, then they need to be clear and highlight as a possible limitation that the number of repeated events were not considered which is important, especially for ADR. In theory, another option would be to model repeated ADR assuming individual data is available. However, I do not think it would add any value given that the events are very small.
Authors' response: We agree that this is a limitation of our study, and we did indeed consider only participants with at least one ADR rather than repeated reactions. We have added a statement to this effect in the discussion (page 8, lines 45-46; page 9, line 1).
Comment 9: -One of the major weaknesses of this work is the unavailability of adverse events data considering that 141(~96%) of the studies were excluded due to incompleteness or nothing at all. This is worrying indeed. Did authors had a chance to find out the reasons behind this -is it because the adverse events were not collected at all in these individual studies or they did not report it or it's something else? In addition, of these excluded studies, was there any information on efficacy/effectiveness of Cfz?
Authors' response: As reported by previous reviews (refs. 44 and 45) , there are remarkably few published clinical investigations of Cfz for the treatment of TB, as we note in line 35 of the Discussion (page 8). Figure 1 shows that within this small universe of studies, few provided information on adverse events. We added to the Discussion (lines 35-37) that a limitation of our analysis was the relative unavailability of AE/ADR data. Comment 11: -General comment -In theory, we know that adverse events are rare events and it requires hundreds of thousands of patients to definitively understand the safety profile of a drug unless the drug is extremely dangerous. I would advise the authors to recalculate the confidence interval using wilson score approach (see attached files) and repeat the fixed and random effect model for the meta analysis. Authors' response: We agree with the reviewer and have conducted the post hoc sensitivity analysis using the Wilson score method to calculate 95% CI. The results, which were largely consistent with the 95% CI previously reported, are provided in the Supplemental Appendix.
Comment 12: -I find it a bit confusing to link the protocol and the manuscript with relation to other objectives such as efficacy/effectiveness of Cfz. Was this a systematic review of systematic reviews because the protocol is silent on this? If so, is it possible to synthesise the effectiveness evidence across all these studies/systematic reviews through an updated meta analysis. Clarification is required?
Authors' response: In the protocol, we set out to assess the published peer-reviewed literature relating to the effectiveness of Cfz, including both studies and systematic reviews. After the protocol was drafted, we were made aware of two systematic reviews of Cfz efficacy that had been published between that time and the drafting of this manuscript. Given the scope of this article focusing primarily on the safety, availability, and management of Cfz, we do not plan to conduct a meta-analysis of efficacy data from these systematic reviews, though we agree that this would be a worthwhile area of future inquiry.
Comment 13: -I would suggest rephrasing the first paragraph on the discussion to include some words of caution on the findings due to limited data on ADRs similar to what has been done on the conclusion section of the abstract. As it stands, if I read it as a reader I might be tempted to over intepret the findings in support of Cfz safety.
Authors' response: We appreciate the reviewer's sentiment and agree that the findings should be interpreted with some measure of caution given the paucity of published literature on Cfz safety. Therefore, we have slightly reworded the Discussion (page 8, line 10), while preserving the readability and flow of the paper. We have augmented our discussion of limitations (page 8, lines 35-46; page 9, lines 1-4), in light of the reviewer's comment.
Comment 14: -The protocol talks about bias assessment using the Cochrane Collaboration's risk of bias framework and categorisation of studies as low, high or unclear which is great. However, there is nothing in the manuscript about this? In addition, the approach described fits well with systematic reviews of randomised controlled trials. I am therefore wondering how issues like randomisation, concealment and blinding say are applicable to this study given that you only considered observational studies? Could you please clarify this or there is something that I'm missing here?
Authors' response: We have provided additional detail in the Supplemental Appendix. As we did not know a priori whether there were any randomized controlled trials in our sample of reviewed papers, we assess bias according to the Cochrane Collaboration's framework. We subsequently found that only observational studies were found, resulting in a "low" assessment for all studies.
Comment 15: -Clarity and additional information is required, especially on some sections which are in the protocol but not even stated in the manuscript. For instance, on bias assessment. They need to rerun the meta-analysis using confidence intervals calculated using the wilson score method.
Authors' response: We appreciate the reviewer's comments and have responded to these points in the above replies.
